In select cases, temporary dose reduction or treatment interruption may be necessary while investigating symptoms, though this decision should be made collaboratively between patient and provider, weighing the benefits of continued therapy against symptom burden
Model fit was assessed using the Hosmer-Lemeshow goodness-of-fit test

Covariates We matched our statistical models for the following covariates: age, sex, T2D complications (kidney, ophthalmic, neurological, and circulatory), comorbidities (alcohol-related disorders, nicotine dependence, hypertension, dyslipidemia, T2D, overweight/obesity, hypertensive disease, cerebrovascular disease, ischemic heart disease, chronic kidney disease, chronic lower respiratory disease, neoplasms, and systemic connective tissue disorders), lipid-lowering agents (HMG-CoA reductase inhibitors, ezetimibe, evolocumab, and alirocumab), antihypertensives (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium-channel blockers, diuretics, and furosemide), anti-anginal or anti-ischemic agents (organic nitrates and ranolazine), heart failure medications (angiotensin receptor-neprilysin inhibitors, eplerenone, vericiguat, digitalis glycosides, SGLT2i, spironolactone, and ivabradine), antiplatelet drugs (aspirin, clopidogrel, ticagrelor, prasugrel, and cangrelor), hemoglobin A1c, and eGFR

While it shares the active ingredient with some weight loss treatments, Ozempic is exclusively approved for blood sugar regulation